5 Key Takeaways

• 1

  QLS-111 is a novel IOP-lowering agent that functions as a vasodilator targeting the distal outflow system.

• 2

  The agent has shown potential to improve perfusion to the optic nerve head while maintaining an excellent safety profile.

• 3

  In clinical studies, QLS-111 demonstrated an additional IOP reduction of approximately 3.2 to 3.6 mmHg when added to latanoprost.

• 4

  The formulation of QLS-111 is preservative-free, isotonic, and pH neutral, making it suitable for daily use.

• 5

  A fixed-dose combination of QLS-111 and latanoprost could provide a promising new treatment option for glaucoma patients.